Director Robert A. Scott of Arcutis Biotherapeutics, Inc. filed a Form 4 on October 28, 2026, disclosing equity awards granted on October 23, 2026, in connection with his service as a non-employee director.

Key Highlights

  • RSU grant: Scott acquired 2,819 restricted stock units on October 23, 2026, at a price of $0, now held directly.
  • First stock option: Scott was awarded an option to purchase 20,507 shares of common stock at an exercise price of $31.20, expiring October 23, 2036.
  • Second stock option: Scott received an additional option to purchase 8,663 shares of common stock at $31.20 per share, also expiring October 23, 2036.
  • RSU vesting: The 2,819 RSUs vest on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to continued service.
  • Option vesting (20,507 shares): One-third of the underlying shares vest on each anniversary of October 23, 2026, with full vesting on the third anniversary, subject to continued service.
  • Option vesting (8,663 shares): 100% of these shares vest on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to continued service.

Director Equity Awards at Arcutis Biotherapeutics on October 23, 2026

According to the Form 4 filed with the SEC on October 28, 2026, Robert A. Scott, who is listed as a director of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), received three equity awards on October 23, 2026. All awards were acquired at a price of $0, reflecting grants made in connection with his role as a non-employee director, as stated in the filing's explanatory footnotes.

The filing reports that the 2,819 RSUs entitle Scott to receive one share of common stock for each RSU upon vesting, which is scheduled to occur on the earlier of June 5, 2027, or immediately before the next annual stockholder meeting, contingent on continued service. Following the transaction, Scott directly holds 2,819 shares of common stock, according to the filing.

Regarding the two stock options, the filing discloses that the larger grant of 20,507 shares vests in equal annual installments of one-third on each of the first three anniversaries of the October 23, 2026 vesting commencement date, while the 8,663-share option vests in full on the earlier of June 5, 2027, or immediately before the next annual meeting, in both cases subject to the director's continued service. Each option carries an exercise price of $31.20 and an expiration date of October 23, 2036. Both options are reported as directly owned by Scott following the transactions.

What Was Disclosed

Robert A. Scott, a director of Arcutis Biotherapeutics, Inc., disclosed the receipt of 2,819 RSUs and two stock options covering 20,507 and 8,663 shares, respectively, all granted on October 23, 2026, as part of his non-employee director compensation.